Mesenchymal Stem Cells Market size was over USD 3.93 billion in 2024 and is anticipated to cross USD 22.59 billion by 2037, witnessing more than 14.4% CAGR during the forecast period i.e., between 2025-2037. In the year 2025, the industry size of mesenchymal stem cells is estimated at USD 4.38 billion.
The growth of the market can be attributed to the growing demand for the treatment of various degenerative and rare diseases, including osteoporosis, cancer, spinal cord injuries, type 1 diabetes, Parkinson's disease, cartilage infection, and ischemic cardiac diseases. The growing prevalence of these ailments is anticipated to be the primary growth driver for the market. According to the data from the World Health Organization (WHO), in 2017 9 million people were suffering from type 1 diabetes. Moreover, a report by the Parkinson's Foundation revealed that around 10 million people worldwide are living with Parkinson’s disease, and 4% of the cases are diagnosed before the age of 50 years.
In addition to these factors, mesenchymal stem cells, or MSCs are extensively used as a regenerative treatment method, which is estimated to boost market growth over the forecast period. Regenerative treatment is used excessively in cardiovascular disease, type 1 diabetes, brain injury tissue repair, and others. Regenerative treatment is a method of using new treatment to cure tissues and organs to recover their function that is lost owing to certain diseases and aging. Furthermore, the growing awareness amongst people regarding early diagnosis and treatment of rare diseases, along with growing healthcare expenditure, is projected to influence market development.
Growth Drivers
Growing Prevalence of Genetic Diseases and Disorders – stem cells are used to repair tissues that are affected or damaged by the genetic mutation. Adult stem cells are highly utilized to cure genetic diseases and disorders. Common types of genetic diseases are Huntington’s, Cystic Fibrosis & Liver disease, and Sickle disease while types of genetic disorders are down syndrome, turner syndrome, Klinefelter syndrome, and others. The higher prevalence of these diseases is expected to hike the market growth over the forecast period. For instance, it was observed that in every 10 people, 6 of them suffer from a condition with genetic background.
Rising Geriatric Population – Elderly population is more prone to get diseases and disorders and the boom in elderly populations worldwide is anticipated to drive market growth during the forecast period. More than 60% of people across the globe will double from 12 to 22% between 2015 and 2050. Meanwhile, as of 2020, there were more people over the age of 60, and it is further expected that approximately 80% of the global geriatric population will dwell in low- and middle-income countries.
Increasing Instances of Cardiovascular Diseases – stem cell therapy is not helpful for all patients of cardiovascular disease but with lifestyle modification, it can be quite a safe and effective alternative treatment. Additionally, stem cells are noticed to be a non-surgical medium to repair damaged heart muscle. For instance, approximately 350,000 people lost their lives on account of coronary heart disease in 2020 across the globe.
Growing Cases of Parkinson’s Disease – it has been observed that mesenchymal stem cell therapy can repair the damaged brain cells by Parkinson’s disease but there is no medical proof that it can completely cure the disease. These cells are used to treat motor symptoms of Parkinson’s disease. For instance, it was estimated that around 88,000 new cases of Parkinson’s disease are diagnosed in the United States every year.
Rising Demand for Stem Cell Treatment in Type 1 Diabetes- there are several documented cases of type 1 diabetes where patients lived for years without needing insulin injections when using cord blood stem cells. For instance, approximately 8 million people across the globe were anticipated to have type 1 diabetes in 2021.
Challenges
|
Base Year |
2024 |
|
Forecast Year |
2025-2037 |
|
CAGR |
14.4% |
|
Base Year Market Size (2024) |
USD 3.93 billion |
|
Forecast Year Market Size (2037 |
USD 22.59 billion |
|
Regional Scope |
|
Type (Human MSCs, Mouse MSCs, Rat MSCs)
The global mesenchymal stem cells market is segmented and analyzed for demand and supply by type into bone marrow, umbilical cord, adipose tissue, molar cell, and others. Out of the three types of irritable bowel syndrome, the umbilical cord segment is estimated to gain the largest market share in the year 2037. The growth of the segment can be attributed to the growing awareness amongst people about the high regenerative properties of umbilical cord cells, along with the increasing trend of storing the cells for the future. It is highly beneficial for treating genetic disorders, immune deficiencies, and several types of cancers. For instance, it was projected that around 450,000 people are currently living with immune deficiency diseases (PIDDs) in USA.
Furthermore, the bone marrow segment is estimated to obtain the second-largest share of the market over the forecast period. Bone marrow mesenchymal stem cells (MSCs) have different properties than other somatic stem cells and that’s the reason they are considered to be unique types of adult stem cells. MSCs are self-renewing multipotent cells and are most suitable for bone tissue regeneration. Cell generation is used in several treatments such as Alzheimer's treatment and to cure spinal cord injuries, cancer, type 1 diabetes, osteoarthritis, Parkinson’s disease, cancer, heart disease, and others. The higher prevalence of these diseases is set to hike the demand for bone marrow mesenchymal stem cells (MSCs). As of 2019, nearly 8 million people across the globe are estimated to be living with Parkinson’s disease. Hence, all these factors are anticipated to influence segment growth positively over the forecast period.
Our in-depth analysis of the global market includes the following segments:
|
By Type |
|
|
By Source |
|
|
By Application |
|
APAC Market Statistics
The Asia Pacific mesenchymal stem cells market, amongst the market in all the other regions, is projected to hold the largest market share by the end of 2037. The growth of the market can be attributed majorly to the increasing awareness regarding healthcare amongst people, along with improving healthcare facilities in the region backed by the rising prevalence of cancer. mesenchymal stem cells have close interaction with cancer cells and it improves the therapeutic sensitivity. Asia is estimated to be a region with a higher prevalence of cancer cases that needs proper rehabilitation. For instance, Asia Pacific accounts for nearly 50% of global cancer incidences. Furthermore, a higher prevalence of cardiovascular diseases such as aortic, coronary heart, stroke, and other peripheral arterial diseases are also estimated to hike the market growth over the forecast period. For instance, in 2019, approximately 10 million deaths are caused by CVDs in Asia.
North American Market Forecast
The North American mesenchymal stem cells market, amongst the market in all the other regions, is projected to hold the second largest share during the forecast period. The growth of the market can be attributed majorly to the increasing adoption of advanced healthcare technologies in developed countries. Moreover, countries, such as, the U.S. and Canada, have a high prevalence of osteoporosis and Parkinson’s disease among other chronic diseases. As per the data by the U.S. Center for Disease Control and Prevention (CDC), 12.6% of adults aged over 50 years have osteoporosis in the femur neck or lumbar spine or both. On the other hand, the surge in the geriatric population with severe chronic and cardiovascular in the region with the need for immediate medical attention is expected to expand the market size over the forecast period. For instance, nearly 95% of adults above 60 in the United States are observed to have at least 2 chronic diseases.
Pluristem Therapeutics Inc. the leading biotechnology company in regenerative medicine, announced the commencement of its multinational Phase III multicenter research on muscle regeneration. The study has been conducted to support muscle regeneration associated with notable trauma such as hip fractures. The company is further noticed to develop placenta-based cell therapy products.
PromoCell GmbH to lead research on immunotherapies through all human primary cells and blood & stem cells, including MHC class I genes HLA-A, -B, and -C.
Author Credits: Radhika Pawar
Copyright © 2024 Research Nester. All Rights Reserved
FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.
Have questions before ordering this report?